Bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid in subjects with different genotypes of the glutamate carboxypeptidase II gene

被引:0
|
作者
Melse-Boonstra, A
Lievers, KJA
Blom, HJ
Verhoef, P
机构
[1] Univ Wageningen & Res Ctr, Div Human Nutr, NL-6700 EV Wageningen, Netherlands
[2] Univ Wageningen & Res Ctr, Wageningen Ctr Food Sci, NL-6700 EV Wageningen, Netherlands
[3] Univ Nijmegen, Dept Pediat & Neurol, Ctr Med, Nijmegen, Netherlands
来源
AMERICAN JOURNAL OF CLINICAL NUTRITION | 2004年 / 80卷 / 03期
关键词
folate bioavailability; polyglutamyl folic acid; serum folate; erythrocyte folate; plasma homocysteine; glutamate carboxypeptidase II gene 1561C -> T polymorphism; genetics;
D O I
暂无
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Before dietary folate is absorbed, polyglutamate folates are deconjugated to monoglutamates by folylpoly-gamma-glutamyl carboxypeptidase in the small intestine. The 1561T allele of the glutamate carboxypeptidase II gene (GCPII), which codes for folylpoly-gamma-glutamyl carboxypeptidase, may impair intestinal absorption of dietary folates. Objective: Our aim was to study the bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid across GCPII 1561 genotypes. Design: In a randomized study, 180 healthy adults aged 50-75 y received 323 nmol monoglutamyl folic acid/d (n = 59), 262 nmol heptaglutamyl folic acid/d (n = 61), or placebo (n = 60) for 12 wk. Genotypes were assessed after the intervention. The bioavailability of heptaglutamyl folic acid relative to that of monoglutamyl folic acid was calculated by using the changes in serum folate concentration in the treatment groups, after correction for changes in the placebo group and for the administered dose. Results: No subjects with the TT genotype were encountered. At baseline, serum and erythrocyte folate concentrations were higher (P < 0.05) in subjects with the CT genotype [16.3 nmol/L (geometric (x) over bar; 95% CI: 13.7,19.3 nmol/L) and 863 nmol/L (735,1012 nmol/L), respectively; n = 19] than in subjects with the CC genotype [ 13.7 (13.1, 14.3) and 685 (652, 721) nmol/L, respectively; n = 161]. Baseline homocysteine concentrations were not significantly different between genotypes. The bioavailability of heptaglutamyl folic acid relative to that of monoglutamyl folic acid was not significantly different between subjects with the CC (64%; 52%, 76%) and CT genotypes (70%; 49%, 91%). Conclusions: The 1561 T allele of the GCPII gene does not impair the bioavailability of polyglutamyl folic acid. However, the allele is associated with higher folate status. This association may be explained by yet unidentified factors controlling the expression of the GCPII gene.
引用
收藏
页码:700 / 704
页数:5
相关论文
共 18 条
  • [1] Bioavailability of heptaglutamyl relative to monoglutamyl folic acid in healthy adults
    Melse-Boonstra, A
    West, CE
    Katan, MB
    Kok, FJ
    Verhoef, P
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2004, 79 (03): : 424 - 429
  • [2] RELATIVE BIOAVAILABILITY OF DEUTERIUM-LABELED MONOGLUTAMYL TETRAHYDROFOLATES AND FOLIC-ACID IN HUMAN-SUBJECTS
    GREGORY, JF
    BHANDARI, SD
    BAILEY, LB
    TOTH, JP
    BAUMGARTNER, TG
    CERDA, JJ
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1992, 55 (06): : 1147 - 1153
  • [3] BIOAVAILABILITY OF DEUTERIUM-LABELED MONOGLUTAMYL FORMS OF FOLIC-ACID AND TETRAHYDROFOLATES IN HUMAN-SUBJECTS
    GREGORY, JF
    BHANDARI, SD
    BAILEY, LB
    TOTH, JP
    BAUMGARTNER, TG
    CERDA, JJ
    FASEB JOURNAL, 1991, 5 (04): : A915 - A915
  • [4] A dual-isotope-labeling method of studying the bioavailability of hexaglutamyl folic acid relative to that of monoglutamyl folic acid in humans by using multiple orally administered low doses
    Melse-Boonstra, Alida
    Verhoef, Petra
    West, Clive E.
    van Rhijn, Johannes A.
    van Breemen, Richard B.
    Lasaroms, Johan J. P.
    Garbis, Spiros D.
    Katan, Martijn B.
    Kok, Frans J.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 84 (05): : 1128 - 1133
  • [5] BIOAVAILABILITY OF FOLIC-ACID AFTER DIFFERENT DOSAGES
    HAGES, M
    PIETRZIK, K
    ERNAHRUNGS-UMSCHAU, 1987, 34 (09): : 298 - 302
  • [6] PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF IRON AND FOLIC-ACID IN HEALTHY-VOLUNTEERS
    SCHUSTER, O
    WEIMANN, HJ
    MULLER, J
    MENKE, A
    MENKE, G
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1993, 43-2 (07): : 761 - 766
  • [7] Folic acid as an antagonist for group II metabotropic glutamate receptors.
    Saitoh, T
    Ishida, M
    Shinozaki, H
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R141 - R141
  • [8] Estimation of relative bioavailability of synthetic folic acid compared to natural folate in the Framingham Study.
    Choumenkovitch, SF
    Jacques, PF
    Dallal, G
    Selhub, J
    FASEB JOURNAL, 2000, 14 (04): : A221 - A221
  • [9] PTEROYLGLUTAMIC (FOLIC) ACID IN DIFFERENT FEEDSTUFFS - THE PTEROYLGLUTAMATE CONTENT AND AN ATTEMPT TO MEASURE THE BIOAVAILABILITY IN PIGS
    MATTE, JJ
    GIRARD, CL
    BRITISH JOURNAL OF NUTRITION, 1994, 72 (06) : 911 - 922
  • [10] Relative bioavailability of iron and folic acid from a new powdered supplement compared to a traditional tablet in pregnant women
    Hartman-Craven, Brenda
    Christofides, Anna
    O'Connor, Deborah L.
    Zlotkin, Stanley
    BMC PREGNANCY AND CHILDBIRTH, 2009, 9